O	0	3	Use
O	4	6	of
B-intervention	7	20	complementary
I-intervention	21	24	and
I-intervention	25	36	alternative
I-intervention	37	45	medicine
O	46	49	and
O	50	56	breast
O	57	63	cancer
O	64	72	survival
O	73	75	in
O	76	79	the
O	80	86	Health
O	86	87	,
O	88	94	Eating
O	94	95	,
O	96	104	Activity
O	104	105	,
O	106	109	and
O	110	119	Lifestyle
O	120	125	Study
O	125	126	.

O	127	130	Use
O	131	133	of
O	134	147	complementary
O	148	151	and
O	152	163	alternative
O	164	172	medicine
O	173	174	(
O	174	177	CAM
O	177	178	)
O	179	181	is
O	182	188	common
O	189	194	among
O	195	201	breast
O	202	208	cancer
O	209	217	patients
O	217	218	,
O	219	222	but
O	223	227	less
O	228	230	is
O	231	236	known
O	237	242	about
O	243	250	whether
O	251	254	CAM
O	255	265	influences
O	266	272	breast
O	273	279	cancer
O	280	288	survival
O	288	289	.

O	290	296	Health
O	297	303	Eating
O	303	304	,
O	305	313	Activity
O	313	314	,
O	315	318	and
O	319	328	Lifestyle
O	329	330	(
O	330	334	HEAL
O	334	335	)
O	336	341	Study
O	342	354	participants
O	355	356	(
O	356	357	n
O	358	359	=
B-total-participants	360	363	707
I-total-participants	363	364	)
O	365	369	were
O	370	379	diagnosed
O	380	384	with
O	385	390	stage
O	391	392	I
O	392	393	-
O	393	397	IIIA
O	398	404	breast
O	405	411	cancer
O	411	412	.

O	413	425	Participants
O	426	435	completed
O	436	437	a
O	438	440	30
O	440	441	-
O	441	446	month
O	447	451	post
O	451	452	-
O	452	461	diagnosis
O	462	471	interview
O	472	481	including
O	482	491	questions
O	492	494	on
O	495	498	CAM
O	499	502	use
O	503	504	(
O	504	511	natural
O	512	520	products
O	521	525	such
O	526	528	as
O	529	536	dietary
O	537	540	and
O	541	550	botanical
O	551	562	supplements
O	562	563	,
O	564	575	alternative
O	576	582	health
O	583	592	practices
O	592	593	,
O	594	597	and
O	598	609	alternative
O	610	617	medical
O	618	625	systems
O	625	626	)
O	626	627	,
O	628	634	weight
O	634	635	,
O	636	644	physical
O	645	653	activity
O	653	654	,
O	655	658	and
O	659	672	comorbidities
O	672	673	.

O	674	682	Outcomes
O	683	687	were
B-outcome-Measure	688	694	breast
I-outcome-Measure	695	701	cancer
I-outcome-Measure	701	702	-
I-outcome-Measure	702	710	specific
O	711	714	and
B-outcome-Measure	715	720	total
I-outcome-Measure	721	730	mortality
O	730	731	,
O	732	737	which
O	738	742	were
O	743	754	ascertained
O	755	759	from
O	760	763	the
O	764	776	Surveillance
O	777	789	Epidemiology
O	790	793	and
O	794	797	End
O	798	805	Results
O	806	816	registries
O	817	819	in
B-location	820	827	Western
I-location	828	838	Washington
O	838	839	,
B-location	840	843	Los
I-location	844	851	Angeles
I-location	852	858	County
O	858	859	,
O	860	863	and
B-location	864	867	New
I-location	868	874	Mexico
O	874	875	.

O	876	879	Cox
O	880	892	proportional
O	893	900	hazards
O	901	911	regression
O	912	918	models
O	919	923	were
O	924	927	fit
O	928	930	to
O	931	935	data
O	936	938	to
O	939	947	estimate
O	948	954	hazard
O	955	961	ratios
O	962	963	(
O	963	965	HR
O	965	966	)
O	967	970	and
O	971	973	95
O	974	975	%
O	976	986	confidence
O	987	996	intervals
O	997	998	(
O	998	1000	CI
O	1000	1001	)
O	1002	1005	for
O	1006	1015	mortality
O	1015	1016	.

O	1017	1023	Models
O	1024	1028	were
O	1029	1037	adjusted
O	1038	1041	for
O	1042	1051	potential
O	1052	1063	confounding
O	1064	1066	by
O	1067	1083	sociodemographic
O	1083	1084	,
O	1085	1091	health
O	1091	1092	,
O	1093	1096	and
O	1097	1103	cancer
O	1103	1104	-
O	1104	1111	related
O	1112	1119	factors
O	1119	1120	.

O	1121	1126	Among
B-total-participants	1127	1130	707
O	1131	1143	participants
O	1143	1144	,
O	1145	1147	70
B-outcome	1148	1154	breast
I-outcome	1155	1161	cancer
I-outcome	1161	1162	-
I-outcome	1162	1170	specific
I-outcome	1171	1177	deaths
O	1178	1181	and
O	1182	1185	149
O	1186	1191	total
B-outcome	1192	1198	deaths
O	1199	1203	were
O	1204	1212	reported
O	1212	1213	.

O	1214	1216	60
O	1216	1217	.
O	1217	1218	2
O	1219	1220	%
O	1221	1223	of
O	1224	1236	participants
O	1237	1245	reported
B-outcome	1246	1249	CAM
I-outcome	1250	1253	use
I-outcome	1254	1258	post
I-outcome	1258	1259	-
I-outcome	1259	1268	diagnosis
O	1268	1269	.

O	1270	1273	The
O	1274	1278	most
O	1279	1285	common
O	1286	1289	CAM
O	1290	1294	were
O	1295	1302	natural
O	1303	1311	products
O	1312	1313	(
O	1313	1315	51
O	1316	1317	%
O	1317	1318	)
O	1319	1328	including
O	1329	1334	plant
O	1334	1335	-
O	1335	1340	based
O	1341	1351	estrogenic
O	1352	1363	supplements
O	1364	1365	(
O	1365	1367	42
O	1368	1369	%
O	1369	1370	)
O	1370	1371	.

O	1372	1384	Manipulative
O	1385	1388	and
O	1389	1393	body
O	1393	1394	-
O	1394	1399	based
O	1400	1409	practices
O	1410	1413	and
O	1414	1425	alternative
O	1426	1433	medical
O	1434	1441	systems
O	1442	1446	were
O	1447	1451	used
O	1452	1454	by
O	1455	1457	27
O	1458	1461	and
O	1462	1464	13
O	1465	1466	%
O	1467	1469	of
O	1470	1482	participants
O	1482	1483	,
O	1484	1496	respectively
O	1496	1497	.

O	1498	1500	No
O	1501	1513	associations
O	1514	1518	were
O	1519	1527	observed
O	1528	1535	between
O	1536	1539	CAM
O	1540	1543	use
O	1544	1547	and
B-outcome	1548	1554	breast
I-outcome	1555	1561	cancer
I-outcome	1561	1562	-
I-outcome	1562	1570	specific
O	1571	1572	(
O	1572	1574	HR
O	1575	1576	1
O	1576	1577	.
O	1577	1579	04
O	1579	1580	,
O	1581	1583	95
O	1584	1585	%
O	1586	1588	CI
O	1589	1590	0
O	1590	1591	.
O	1591	1593	61
O	1593	1594	-
O	1594	1595	1
O	1595	1596	.
O	1596	1598	76
O	1598	1599	)
O	1600	1602	or
B-outcome	1603	1608	total
I-outcome	1609	1618	mortality
O	1619	1620	(
O	1620	1622	HR
O	1623	1624	0
O	1624	1625	.
O	1625	1627	91
O	1627	1628	,
O	1629	1631	95
O	1632	1633	%
O	1634	1636	CI
O	1637	1638	0
O	1638	1639	.
O	1639	1641	63
O	1641	1642	-
O	1642	1643	1
O	1643	1644	.
O	1644	1646	29
O	1646	1647	)
O	1647	1648	.

O	1649	1662	Complementary
O	1663	1666	and
O	1667	1678	alternative
O	1679	1687	medicine
O	1688	1691	use
O	1692	1695	was
O	1696	1699	not
O	1700	1710	associated
O	1711	1715	with
O	1716	1722	breast
O	1723	1729	cancer
O	1729	1730	-
O	1730	1738	specific
O	1739	1748	mortality
O	1749	1751	or
O	1752	1757	total
O	1758	1767	mortality
O	1767	1768	.

O	1769	1779	Randomized
O	1780	1790	controlled
O	1791	1797	trials
O	1798	1801	may
O	1802	1804	be
O	1805	1811	needed
O	1812	1814	to
O	1815	1827	definitively
O	1828	1832	test
O	1833	1840	whether
O	1841	1846	there
O	1847	1849	is
O	1850	1854	harm
O	1855	1857	or
O	1858	1865	benefit
O	1866	1870	from
O	1871	1874	the
O	1875	1880	types
O	1881	1883	of
O	1884	1887	CAM
O	1888	1896	assessed
O	1897	1899	in
O	1900	1904	HEAL
O	1905	1907	in
O	1908	1916	relation
O	1917	1919	to
O	1920	1929	mortality
O	1930	1938	outcomes
O	1939	1941	in
O	1942	1948	breast
O	1949	1955	cancer
O	1956	1965	survivors
O	1965	1966	.
